Checkpoint targets and agents in clinical development
| Target . | Agent(s) . | Type . | FDA approval . | Trials in myeloma . |
|---|---|---|---|---|
| CTLA-4 | Ipilimumab | Human IgG1 | Melanoma | Combination and in transplant setting |
| Tremelimumab | Human IgG2 | NA | In transplant setting | |
| PD-1 | Pembrolizumab | Humanized IgG4 | Melanoma, lung | 50% ORR with len/dex (KEYNOTE-023), 60% ORR with pom/dex (KEYNOTE-183), phase III combinations ongoing |
| Nivolumab | Human IgG4 | Melanoma, kidney, lung | 63% SD (1 CR) as single agent, ongoing combination trials | |
| PDR001 | Humanized IgG4 | NA | Combination trial | |
| PD-L1 | Atezolizumab | Humanized IgG1 | Bladder | Single-agent, combination, and in transplant setting |
| Durvalumab | Human IgG1 | NA | Combination and in transplant setting | |
| KIR | Lirilumab | Human IgG4 | NA | Single agent and combination |
| LAG-3 | BMS986016 | Human IgG4 | NA | Phase 1 trial including myeloma |
| LAG525 | Humanized IgG4 | NA | In other malignancies | |
| NKG2A | Monalizumab | Humanized IgG4 | NA | In other malignancies |
| TIM-3 | MBG453 | Antibody | NA | Alone and in combination in other malignancies |
| TSR-022 | Antibody | NA | Alone and in combination in other malignancies | |
| VISTA | JNJ-61610588 | Human IgG1 | NA | In other malignancies |
| CA-170 | Oral small molecule | NA | In other malignancies | |
| CD47 | TTI-621 | Ab-like fusion | NA | Phase 1 trial including myeloma |
| CC-90002 | Antibody | NA | Phase 1 trial including myeloma |
| Target . | Agent(s) . | Type . | FDA approval . | Trials in myeloma . |
|---|---|---|---|---|
| CTLA-4 | Ipilimumab | Human IgG1 | Melanoma | Combination and in transplant setting |
| Tremelimumab | Human IgG2 | NA | In transplant setting | |
| PD-1 | Pembrolizumab | Humanized IgG4 | Melanoma, lung | 50% ORR with len/dex (KEYNOTE-023), 60% ORR with pom/dex (KEYNOTE-183), phase III combinations ongoing |
| Nivolumab | Human IgG4 | Melanoma, kidney, lung | 63% SD (1 CR) as single agent, ongoing combination trials | |
| PDR001 | Humanized IgG4 | NA | Combination trial | |
| PD-L1 | Atezolizumab | Humanized IgG1 | Bladder | Single-agent, combination, and in transplant setting |
| Durvalumab | Human IgG1 | NA | Combination and in transplant setting | |
| KIR | Lirilumab | Human IgG4 | NA | Single agent and combination |
| LAG-3 | BMS986016 | Human IgG4 | NA | Phase 1 trial including myeloma |
| LAG525 | Humanized IgG4 | NA | In other malignancies | |
| NKG2A | Monalizumab | Humanized IgG4 | NA | In other malignancies |
| TIM-3 | MBG453 | Antibody | NA | Alone and in combination in other malignancies |
| TSR-022 | Antibody | NA | Alone and in combination in other malignancies | |
| VISTA | JNJ-61610588 | Human IgG1 | NA | In other malignancies |
| CA-170 | Oral small molecule | NA | In other malignancies | |
| CD47 | TTI-621 | Ab-like fusion | NA | Phase 1 trial including myeloma |
| CC-90002 | Antibody | NA | Phase 1 trial including myeloma |
FDA, US Food and Drug Administration; NA, not applicable.